Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline.
Skudicky
D
D
Department of Cardiology Baragwanath Hospital University of the Witwatersrand Johannesburg, South Africa. dskudi@icon.co.za
Sliwa
K
K
Bergemann
A
A
Candy
G
G
Sareli
P
P
D000328:Adult; D017209:Apoptosis / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D002311:Cardiomyopathy, Dilated / Q000097:blood* / Q000188:drug therapy; D016022:Case-Control Studies; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D018487:Ventricular Dysfunction, Left / Q000097:blood*; D019014:fas Receptor / Q000097:blood*
D015415:Biomarkers; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor; D010431:Pentoxifylline